The latest progress of stamp duty in Hong Kong has come!If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.This afternoon, the Government of the Hong Kong Special Administrative Region welcomed the passage of the Stamp Duty Legislation (Miscellaneous Amendments) Bill 2024 by the Legislative Council, which exempted the transfer of shares or units of real estate investment trusts and the securities distribution business of option makers, and revised the stamp duty collection arrangements under the paperless securities market system in Hong Kong.
So will heavyweights and large-cap stocks exert their strength? Looking at the trend of SSE 50, it is still very possible, because at present, the monthly trend of SSE 50 index is intact, and the index remains above the offensive line and above the long-term trend line. At present, it has the foundation to start a big market. Looking back, the index must remain above the monthly offensive line in all big markets, so this is a prerequisite. Since it is also available now, we can certainly expect something.If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.The latest CPI data will be released tonight. The market expects the overall inflation rate to be 2.7%, 0.1 percentage point higher than that in October, and the core inflation rate is expected to be 3.3%, which is the same as that in October. Although the forecast data shows that the suppression of inflation by monetary policy is close to stagnation, it has dropped sharply compared with the previous peak of 9%. At present, the latest FEDWATCH data shows that the possibility of the Fed cutting interest rates next Tuesday is over 80%.
A major breakthrough! Quantum technology frenzy strikesDezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Federal Reserve's December Outlook
Strategy guide 12-13
Strategy guide
12-13
Strategy guide 12-13
Strategy guide 12-13